Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Clinical Applications

Официальное название

Study on the Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Application in Cognitive Assessment, Diagnosis, and Precision Treatment

Обзор

Previous and our studies have shown that cognitive impairments are core symptoms of three major psychiatric disorders-schizophrenia, bipolar disorder, and major depressive disorder, and are associated with underlying brain dysfunction. However, the specific brain networks involved in cognitive impairments (cognitive impairment brain networks) in these disorders, as well as whether their neuroimaging features can be applied to cognitive assessment, diagnosis, and precision treatment, remain unclear. This study aims to identify cognitive impairment brain networks using publicly available large-scale datasets and clinical research, and to explore whether the neuroimaging features of these networks can be utilized for cognitive assessment, diagnosis, and treatment response prediction. First, a "sensitive cognitive assessment model for major psychiatric disorders" will be established through meta-analysis based on sensitive scales. Second, cognitive impairment brain networks will be identified using publicly available large-scale datasets combined with the lesion network mapping method, and their validity will be examined by assessing their non-randomness, reproducibility, symptom specificity, and disease specificity. Third, cognitive assessment and diagnostic models will be developed based on neuroimaging features of these networks. Finally, a combination of cross-sectional and longitudinal study designs will be used in a clinical trial to validate the identified networks and models, and a treatment response prediction model will be established based on the neuroimaging features of cognitive impairment brain networks. This study will advance the understanding of the neurophysiological mechanisms underlying cognitive impairment in major psychiatric disorders, promote the application of neuroimaging in psychiatric diagnosis and treatment, and improve traditional diagnostic, therapeutic, and cognitive assessment approaches.

Вмешательства

• Устройство repetitive transcranial magnetic stimulation (rTMS)
  Patients will receive repetitive transcranial magnetic stimulation (rTMS) targeting the dorsolateral prefrontal cortex (dlPFC).

Первичные конечные точки

• Cognitive changes [Срок оценки: From enrollment to the end of treatment at 8 weeks]

Критерии участия

Критерии включения

• 1, For Patients (SZ, BD, MDD):

Diagnosis of schizophrenia (SZ), bipolar disorder (BD), or major depressive disorder (MDD) according to standard diagnostic criteria

First-episode drug-naïve patients or patients who have relapsed after discontinuing medication for more than one month

Aged 18-60 years

Completion of at least 6 years of formal education

2, For Healthy Controls:

Aged 18-60 years

Completion of at least 6 years of formal education

No current or past psychiatric disorders

No first-degree relatives with psychiatric disorders

No history of treatment with psychotropic medications or physical therapy for psychiatric disorders

Критерии исключения

• Prior use of psychotropic medications or receipt of physical treatment for psychiatric disorders (for patient group)

Contraindications to MRI scanning

History of brain injury

History of substance abuse

Presence of other neurological disorders

Presence of severe medical or systemic physical illnesses.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение

Нерандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Китай · 1 центр

• Second Xiangya Hospital — Чанша

Идентификаторы

NCT: NCT07444463 · 20270101GWB

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗